CN104023733A - 癌症的免疫原性治疗 - Google Patents

癌症的免疫原性治疗 Download PDF

Info

Publication number
CN104023733A
CN104023733A CN201280059421.0A CN201280059421A CN104023733A CN 104023733 A CN104023733 A CN 104023733A CN 201280059421 A CN201280059421 A CN 201280059421A CN 104023733 A CN104023733 A CN 104023733A
Authority
CN
China
Prior art keywords
immunomodulator
cancer
tumor
therapy
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280059421.0A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·艾科
赛特温德·穆旦
约翰·格兰奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heroes And Models' Degree Human Relations Medical Co
Original Assignee
Heroes And Models' Degree Human Relations Medical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heroes And Models' Degree Human Relations Medical Co filed Critical Heroes And Models' Degree Human Relations Medical Co
Publication of CN104023733A publication Critical patent/CN104023733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201280059421.0A 2011-12-02 2012-12-03 癌症的免疫原性治疗 Pending CN104023733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
GB1120779.2 2011-12-02
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (1)

Publication Number Publication Date
CN104023733A true CN104023733A (zh) 2014-09-03

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280059421.0A Pending CN104023733A (zh) 2011-12-02 2012-12-03 癌症的免疫原性治疗

Country Status (15)

Country Link
US (4) US20140356397A1 (enExample)
EP (1) EP2785361B1 (enExample)
JP (1) JP6085611B2 (enExample)
KR (1) KR20140097419A (enExample)
CN (1) CN104023733A (enExample)
AU (1) AU2012343536B2 (enExample)
BR (1) BR112014012880A2 (enExample)
CA (1) CA2857429A1 (enExample)
GB (1) GB201120779D0 (enExample)
IL (1) IL232890A0 (enExample)
IN (1) IN2014MN00955A (enExample)
MX (1) MX2014006511A (enExample)
RU (1) RU2014121335A (enExample)
SG (1) SG11201402396XA (enExample)
WO (1) WO2013079980A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
EP3043863B1 (en) 2013-09-11 2019-12-04 The Board of Trustees of the Leland Stanford Junior University Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies
KR102171496B1 (ko) 2013-12-05 2020-10-30 알에프이엠비 홀딩스, 엘엘씨 면역 요법을 위한 보조 메커니즘으로서의 고주파 전기막 파괴(rf-emb)에 의한 암 항원의 항원표출세포로의 개선된 표출 시스템
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
TWI911597B (zh) 2016-01-15 2026-01-11 美商Ｒｆｅｍｂ控股有限公司 癌症之免疫治療
AU2017249500A1 (en) * 2016-04-14 2018-11-01 Feldreich Caro Ruiz AB An apparatus for use in irradiation therapy comprising ionization module and UV-light source
US11980769B2 (en) 2017-03-28 2024-05-14 Emblation Limited Stenosis treatment
CN111479571A (zh) 2017-07-21 2020-07-31 瓦里安医疗系统公司 超高剂量率辐射和治疗剂的使用方法
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
US20220088231A1 (en) 2018-12-03 2022-03-24 Fusion Pharmaceuticals Inc. Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
CN114980930A (zh) * 2019-12-27 2022-08-30 志瑞亚新药工业株式会社 癌症治疗方法及药物
US20240216443A1 (en) * 2021-07-27 2024-07-04 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
EP2010216A2 (en) * 2006-03-24 2009-01-07 Donald L. Morton Mycobacterial immunotherapy for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
EP1173203A2 (en) 1999-04-23 2002-01-23 QLT Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
WO2007050405A2 (en) 2005-10-21 2007-05-03 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
EP2683386B1 (en) * 2011-03-09 2017-07-05 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
AU2012273182A1 (en) 2011-06-21 2014-01-16 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
SG2014008304A (en) 2012-02-01 2014-06-27 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA3156357A1 (en) 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016207646A1 (en) 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US20210299187A1 (en) 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
EP2010216A2 (en) * 2006-03-24 2009-01-07 Donald L. Morton Mycobacterial immunotherapy for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA X1等: ""Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment"", 《MED HYPOTHESES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Also Published As

Publication number Publication date
GB201120779D0 (en) 2012-01-11
WO2013079980A1 (en) 2013-06-06
IL232890A0 (en) 2014-07-31
NZ624994A (en) 2016-10-28
MX2014006511A (es) 2014-12-05
RU2014121335A (ru) 2016-01-27
EP2785361A1 (en) 2014-10-08
AU2012343536B2 (en) 2017-08-24
CA2857429A1 (en) 2013-06-06
JP6085611B2 (ja) 2017-02-22
US11554166B2 (en) 2023-01-17
KR20140097419A (ko) 2014-08-06
EP2785361B1 (en) 2018-11-28
BR112014012880A2 (pt) 2017-06-13
US20190224294A1 (en) 2019-07-25
US20200338181A1 (en) 2020-10-29
IN2014MN00955A (enExample) 2015-04-24
US20140356397A1 (en) 2014-12-04
JP2014533743A (ja) 2014-12-15
AU2012343536A1 (en) 2014-06-05
US20230149525A1 (en) 2023-05-18
SG11201402396XA (en) 2014-10-30
US11318193B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
US20230149525A1 (en) Immunogenic treatment of cancer
Tan et al. The role of photodynamic therapy in triggering cell death and facilitating antitumor immunology
Moy et al. Combinatorial immunotherapy and nanoparticle mediated hyperthermia
Breton et al. Microsecond and nanosecond electric pulses in cancer treatments
JP2025185047A (ja) がんの免疫学的処置
US9526911B1 (en) Immune mediated cancer cell destruction, systems and methods
Bai et al. Advancements and challenges in brain cancer therapeutics
JP2014533743A5 (enExample)
Séguier et al. Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer
Tranberg Local destruction of tumors and systemic immune effects
Holtermann et al. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors: A. Holtermann et al.
CN110478627A (zh) 一种结合石墨烯红外热疗的激光癌症治疗仪
Guo et al. Role of endoscopic ultrasound in treatment of pancreatic cancer
Hwang et al. Endoscopic ultrasound-guided local therapy for pancreatic neoplasms
Cabuy Hyperthermia in cancer treatment
CN104083205A (zh) 一种肿瘤治疗系统和方法
Lou et al. Multimodal thermal therapy for solid tumor: a new interventional immunomodulatory therapy
NZ624994B2 (en) Immunogenic treatment of cancer
Stam et al. From local to systemic treatment: leveraging antitumor immunity following irreversible electroporation
Saito et al. Enhanced local dendritic cell activity and tumor‐specific immunoresponse in combined radiofrequency ablation and interleukin‐2 for the treatment of human head and neck cancer in a murine orthotopic model
Peng et al. Tumor therapeutic modes
Yang et al. Endoscopic Ultrasound‐Guided Therapies in Pancreatic Neoplasms
RU2530523C2 (ru) Способ противоопухолевой иммунотерапии
US20210154296A1 (en) Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients
Di Matteo et al. Endoscopic Ultrasound-Guided Therapies for Solid Pancreatic Tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140903

WD01 Invention patent application deemed withdrawn after publication